Download Global Lung Cancer Vaccine Market and Pipeline Outlook 2022 Report

“Global Lung Cancer Vaccine Market and Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the global lung cancer vaccine market. Currently there are 3 lung cancer vaccines commercially available in the market. This report analyzes the ongoing clinical trial of 30 lung cancer vaccines in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the lung cancer vaccines. Currently there are 9 lung cancer vaccines in advance Phase-II clinical trials followed by 8 vaccines Phase-I/II trials.

Lung cancer is emerging as one of the most lethal malignancy having high morbidity and mortality rates across the world. High mortality rates, high unmet medical necessities and modest efficacy of presently available lung cancer therapeutics have encouraged the demand for better and efficient lung cancer vaccines. More funds are being diverted into research and development segment to come up with lung cancer vaccine having high safety and efficacy profiles. Pharmaceutical companies have recognized the marketing potential of these vaccines in generating significant revenues and providing efficient medical care to patients across the world. Lung cancer vaccine market is largely untapped and offers significant opportunities to pharmaceutical companies to occupy large market shares across the globe.

At present majority of the lung cancer vaccines are in experimental stage and are still stuck in clinical trials due to which large unmet medical demands are still to be fulfilled. Boehringer Ingelheim and CureVac are developing lung cancer vaccine called CV9202 for the treatment of lung cancer which is at higher phase of clinical trials. GlaxoSmithKline is developing MAGE-A3 lung cancer vaccine which is also under investigation for other malignancies. Cell Genesys pharmaceutical company is developing GVAX for lung cancer and many clinical end points have been achieved during investigation.

Early market introduction of these drugs will be the major factor responsible for the increased marketing potential. Over time, they are expected to generate significant revenues owing to their safety and efficacy levels but till then this gap will be filled by other therapeutics. Further, those lung cancer vaccines which will make late entry have to face competition with previously marketed lung cancer vaccines giving them severe competition. This shows that pharmaceutical companies have to introduce their products in market as soon as possible to occupy major market shares across the globe. Thus, impact of early entrant will be more in global market and help them to generate significant revenues for some time before entry of worthy competitors.

Many pharmaceutical companies have already introduces cancer vaccines in global market and lung cancer segment is expected to get its first contender in coming years. Addition of lung cancer vaccines in this segment will further increase the size of global cancer vaccine market. Several other products belonging to different cancer indication will be entering in the global market leading to further increase in the market size. Advent of lung cancer vaccines is expected to improve this situation by increasing present survival rates and improve quality of life. Introduction of lung cancer vaccines are expected to gain major market shares among other cancer vaccines due to large patient population as compared to other disease indication.

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink: https://www.kuickresearch.com/report-global-lung-cancer-vaccine-market-and-pipeline-outlook-2022.php

What are Cancer Vaccines?

Mechanism of Cancer Vaccines
2.1 Idiotype Cancer Vaccine Mechanism
2.2 Cellular Cancer Vaccines Mechanism
2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
2.4 Peptide Cancer Vaccine Mechanism
2.5 Tumor Host Interaction Cancer Vaccine Mechanism

Overview of Lung Cancer Proliferation
3.1 Lung Cancer Invasion
3.1.1 Transformation of Normal Cell into Cancerous Cell
3.1.2 Tumor Heterogeneity and Cancer Stem Cells
3.1.3 Dissemination of Tumor Cell and Cell Motility
3.2 Lung Cancer Metastasis
3.2.1 Angiogenesis and Lymphangiogenesis
3.2.2 Intravasation, Circulation and Extravasation

Lung Cancer Vaccine Mechanism
4.1 Mechanism of Lung Cancer Vaccination
4.2 Rationale for Using Lung Cancer Vaccines
4.2.1 Regulatory T- Lymphocytes (Tregs)
4.2.2 Macrophages

Clinical Trials of Lung Cancer Vaccines

Global Lung Cancer Incidence Rate
6.1 U.S
6.2 Europe
6.3 Asia
6.4 Rest of the World

Global Lung Cancer Vaccine Market Overview
7.1 Current Market Scenario
7.2 Global Lung Cancer Vaccine Pipeline Overview
7.3 Global Lung Cancer Vaccine Market Future Prospects

Need for Personalized Breast Cancer Vaccines

Lung Cancer Vaccine Clinical Pipeline by Company and Phase
9.1 Preclinical
9.2 Phase-I
9.3 Phase-II

Non Small Cell Lung Cancer Vaccine Clinical Pipeline by Company and Phase
10.1 Research
10.2 Preclinical
10.3 Phase-I
10.4 Phase-I/II
10.5 Phase-II
10.6 Phase-II/III
10.7 Phase-III

Small cell lung Cancer Vaccine Clinical Pipeline by Company and Phase
11.1 Phase-II

Marketed Lung Cancer Vaccine Clinical and Patent Insight
12.1 Epidermal Growth Factor Cancer Vaccine
12.2 Mycidac-Candtrade;
12.3 Racotumomab (Vaxira)

No Development Reported and Discontinued Lung Cancer Vaccine Clinical Pipeline by Company, Indication and Phase
13.1 No Development Reported
13.2 Discontinued
13.3 Suspended

Competitive Landscape
14.1 Argos Therapeutics
14.2 Boehringer Ingelheim
14.3 Cadila Pharmaceuticals
14.4 CureVac
14.5 Eli Lily
14.6 Galaxo
14.7 ImClone Systems
14.8 Inovio Pharmaceuticals
14.9 Merck
14.10 NewLink Genetics
14.11 Northwest Biotherapeutics
14.12 Ono Pharmaceutical
14.13 Oncothyreon Incorporation
14.14 OSE Immunotherapeutics

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Kuick Research
New Delhi - 110001
India
+91-11-47067990

This release was published on openPR.